AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointments of Andreas Bader as Senior Vice President of Research & Development, and Joshua Carle as Vice President of Business Development.
Dr. Andreas Bader joined Triumvira in 2018. Dr. Bader is a seasoned biotech executive with more than 20 years’ experience in oncology drug discovery and development, and business and research strategies. Previously, Dr. Bader acted as Co-Founder and CEO of Orros Biotherapeutics LLC, and as a scientific Co-Founder of Mirna Therapeutics, Inc., where he held multiple leading positions in R&D and led research programs from discovery to the completion of a Phase 1 clinical trial. Prior to Mirna, Dr. Bader functioned as the Scientific Lead of the microRNA therapeutics program at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, received his PhD in Biochemistry and his MSc degree in Biology from the University of Innsbruck, Austria.
Joshua Carle, MBA, is a cross-functional executive with over 15 years of strategic transaction and R&D investment experience while in Management Consulting and BioPharma. Mr. Carle has led or advised more than fifty potential strategic transactions, resulting in the successful execution of greater than $2 billion in disclosed deal value and committed R&D funds. Mr. Carle joins from Pfizer Inc., where he drove BD strategy, commercial assessments, and broad transaction support for licensing/M&A efforts for Pfizer Oncology. Previously, Mr. Carle held roles of increasing responsibility in business development activities at Daiichi Sankyo Inc. and Clearview Projects Inc., a strategic advisory firm focused on licensing/M&A for the BioPharma industry. Mr. Carle received his undergraduate degree in Economics from the University of Pennsylvania and MBA from the Villanova School of Business.
Paul Lammers, MD, MSc., President and CEO of Triumvira Immunologics commented, “The addition of Andy and Josh brings two seasoned professionals to our company, which will help us tremendously as we build Triumvira into a significant player in the exciting and rapidly expanding field of engineered T-cell therapy in immuno-oncology. I am looking forward to their many contributions as we bring our TAC product candidates into clinical development and ultimately towards commercialization, alone as well as in collaboration with our business partners.”
About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com.
